Global Diabetic Retinopathy Market Growth (Status and Outlook) 2024-2030

Global Diabetic Retinopathy Market Growth (Status and Outlook) 2024-2030

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease.

The global Diabetic Retinopathy market size is projected to grow from US$ 7589.9 million in 2023 to US$ 11750 million in 2030; it is expected to grow at a CAGR of 6.4% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Diabetic Retinopathy Industry Forecast” looks at past sales and reviews total world Diabetic Retinopathy sales in 2023, providing a comprehensive analysis by region and market sector of projected Diabetic Retinopathy sales for 2024 through 2030. With Diabetic Retinopathy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diabetic Retinopathy industry.

This Insight Report provides a comprehensive analysis of the global Diabetic Retinopathy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diabetic Retinopathy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diabetic Retinopathy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diabetic Retinopathy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diabetic Retinopathy.

According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.

Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.

This report presents a comprehensive overview, market shares, and growth opportunities of Diabetic Retinopathy market by product type, application, key players and key regions and countries.

Segmentation by type
Laser Surgery
Injection of Corticosteroids
Anti-VEGF Drugs
Vitrectomy

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer
Roche
Novartis
TEVA
Alimera Sciences
Regeneron Pharmaceuticals
Boehringer Ingelheim
Kowa Group
Ohr Pharmaceutical
Quark Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.